Skip to main content
Caplight Logo









GICMED

GICMED

Private
YaoundéHealthcare & Life Scienceshttps://gicmed.org

Last Round

Grant

Jul 3, 2025

Total Funding Raised

$195,000

Company Overview

GICMED operates in Healthcare & Life Sciences and is based in Yaoundé. Its latest recorded funding round was a Grant round in July 2025.

GICMED is a MedTech company that provides cost-effective telemedicine and digital microscopy solutions for the early detection of breast and cervical cancer in underserved regions.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, Medical Devices, Medical Imaging, Health IoT

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Revenue Share

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

GICMED Comparables

Compare GICMED with similar companies based on industry and business-model similarity.

GICMED comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
UE LifeSciences
79%
Liger Medical
79%
Gynius Plus AB
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

GICMED Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 3, 2025
GrantAug 11, 2021
GrantAug 19, 2020
GrantSep 24, 2019
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

GICMED Investors

Notable investors and investment history

GICMED investors
InvestorRounds
USAIDGrant
United Nations Population FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2025

    $20K grant received from the United Nations Population Fund.

  • Aug 11, 2021

    $50K grant received from IronPort Systems.

Book a demo to see all signals

For institutional investors. Book with your work email.

GICMED Filings

Explore SEC and related filing metadata, where available.

GICMED filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about GICMED's valuation, stock price, and market status.

Is GICMED a public or private company?

GICMED is a private company.

What is the current stock price of GICMED?

GICMED is a private company, so its shares have no public market price. Caplight tracks GICMED's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is GICMED worth (valuation)?

Valuation information for GICMED is not publicly available.

Can I buy GICMED stock?

GICMED shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was GICMED's last funding round?

GICMED's most recent funding round was Grant on July 3, 2025.

Who are the main investors in GICMED?

Key investors in GICMED include USAID, United Nations Population Fund.

Will GICMED IPO soon?

No public IPO plans have been announced for GICMED.

How can I track GICMED secondary market activity?

Caplight tracks bids, offers, and trades in GICMED's shares on secondary markets.

Firmographic Details

HeadquartersYaoundé
Year Founded2019
Last FundingJul 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?